News
NRBO
--
0.00%
--
2 Falling Knives to Catch
GuruFocus News · 5d ago
NeuroBo Pharma gains 6% on approval of CVR amendment for Gemcabene
NeuroBo Pharmaceuticals (NRBO) perks up 6% premarket after receiving approval of an amendment to its Contingent Value Rights ((CVR)) agreement from a majority of CVR holders. The CVRs were distributed to the
Seekingalpha · 03/24 12:45
RIOT, SRNE, GNUS and IPHI among premarket gainers
Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4
Seekingalpha · 03/24 12:23
DJ NeuroBo Pharmaceuticals Gets Approval to Amend Contingent Value Rights Deal
Dow Jones · 03/24 12:13
NeuroBo Pharmaceuticals Receives Approval For Amendment Of Contingent Value Rights For Gemcabene From A Majority Of Shareholders
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Contingent Value Rights (CVR) agreement from a majority of
Benzinga · 03/24 12:05
BRIEF-Dong-A ST Co Reports 13% Stake In NeuroBo Pharmaceuticals
reuters.com · 03/11 13:14
NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that Company management will participate in the upcoming H.C. Wainwright Global Life Sciences Conference taking place virtually from , 2021. 
PR Newswire - PRF · 03/05 13:30
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 03/05 13:15
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer effective February 1, 2021. A seasoned financial and...
BusinessWire · 03/03 12:00
NeuroBo Pharmaceuticals Receives Intention To Grant Patent Today From European Patent Office Titled 'COMPOSITION CONTAINING PORIA COCOS BARK EXTRACT FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS'
https://register.epo.org/application?number=EP19210811&tab=main
Benzinga · 03/02 14:54
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23)
Benzinga · 02/24 12:30
DJ NeuroBo Pharmaceuticals Price Target Cut to $16.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 02/01 11:34
DJ NeuroBo Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/01 11:34
BRIEF-Neurobo Pharmaceuticals Inc Files For Stock Shelf Of Up To 5 Million Shares By Selling Stockholder - SEC Filing
reuters.com · 01/25 22:34
*DJ NeuroBo Pharma: Each Shr and Corresponding Warrant at $4 Each for Proceedsof $10M
Dow Jones · 01/21 21:09
*DJ NeuroBo Pharmaceuticals Closes $10.0 M Private Placement
Dow Jones · 01/21 21:07
NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement
, /PRNewswire/ -- (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of an aggregate 2,500,000 shares of its common stock and warrants to purchase up to an aggregate of 2,500,...
PR Newswire - PRF · 01/21 21:06
Press Release: NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement
Dow Jones · 01/21 21:05
NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of an aggregate 2,500,000 shares of its common stock and warrants to purchase up to an aggregate...
PR Newswire · 01/21 21:05
Mid-Afternoon Market Update: Nasdaq Surges 1.5%; Aclaris Therapeutics Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.42% to 30,944.82 while the NASDAQ rose 1.50% to 13,193.24. The S&P also rose, gaining 0.85% to 3,800.32.
Benzinga · 01/19 19:58
Webull provides a variety of real-time NRBO stock news. You can receive the latest news about NeuroBo Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRBO
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.